BioArctic’s partner Eisai launches Leqembi in South Korea to treat MCI due to AD or mild AD dementia: Stockholm, Sweden Friday, November 29, 2024, 16:00 Hrs [IST] BioArctic ABs ...

Eisai (ESAIY) and Biogen (BIIB) announced that the humanized anti-soluble aggregated amyloid-beta, or Abeta, monoclonal antibody Leqembi has ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

Japanese drugmaker Eisai today that the humanized antisoluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) has been launched in South Korea.

Biogen Inc.’s BIIB Japan-based partner, Eisai announced that the European Medicines Agency’s (EMA) Committee for Medicinal ...

Eisai and the National Center of Neurology and Psychiatry in Tokyo will study the link between APOE genotype and safety and efficacy of Leqembi.

CHICAGO--The benefit of Eisai and Biogen’s Alzheimer’s drug Leqembi in patients with early-stage Alzheimer’s appears to increase with continued use with no new safety issues, according to ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

The European Medicines Agency (EMA) has recommended market approval for Alzheimer’s antibody Leqembi (lecanemab), reversing ...

TOKYO and CAMBRIDGE, Mass., Nov 28, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody ...

The negative opinion was reportedly due to a brain swelling side effect called amyloid-related imaging abnormalities associated with the use of anti-amyloid therapies like Leqembi. Eisai requested ...